These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24356715)

  • 1. 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder.
    Grant PJ; Joseph LA; Farmer CA; Luckenbaugh DA; Lougee LC; Zarate CA; Swedo SE
    Neuropsychopharmacology; 2014 May; 39(6):1453-9. PubMed ID: 24356715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder.
    Grant P; Lougee L; Hirschtritt M; Swedo SE
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):761-7. PubMed ID: 18315448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study.
    Li F; Welling MC; Johnson JA; Coughlin C; Mulqueen J; Jakubovski E; Coury S; Landeros-Weisenberger A; Bloch MH
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):32-37. PubMed ID: 31800306
    [No Abstract]   [Full Text] [Related]  

  • 4. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study.
    Emamzadehfard S; Kamaloo A; Paydary K; Ahmadipour A; Zeinoddini A; Ghaleiha A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    Psychiatry Clin Neurosci; 2016 Aug; 70(8):332-41. PubMed ID: 27106362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
    McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
    Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study.
    Arabzadeh S; Shahhossenie M; Mesgarpour B; Rezaei F; Shalbafan MR; Ghiasi Z; Akhondzadeh S
    Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28485008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Double-Blind Randomized Placebo-Controlled Pilot Study of Azithromycin in Youth with Acute-Onset Obsessive-Compulsive Disorder.
    Murphy TK; Brennan EM; Johnco C; Parker-Athill EC; Miladinovic B; Storch EA; Lewin AB
    J Child Adolesc Psychopharmacol; 2017 Sep; 27(7):640-651. PubMed ID: 28358599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
    Coric V; Taskiran S; Pittenger C; Wasylink S; Mathalon DH; Valentine G; Saksa J; Wu YT; Gueorguieva R; Sanacora G; Malison RT; Krystal JH
    Biol Psychiatry; 2005 Sep; 58(5):424-8. PubMed ID: 15993857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
    Storch EA; Wilhelm S; Sprich S; Henin A; Micco J; Small BJ; McGuire J; Mutch PJ; Lewin AB; Murphy TK; Geller DA
    JAMA Psychiatry; 2016 Aug; 73(8):779-88. PubMed ID: 27367832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.
    Pittenger C; Bloch MH; Wasylink S; Billingslea E; Simpson R; Jakubovski E; Kelmendi B; Sanacora G; Coric V
    J Clin Psychiatry; 2015 Aug; 76(8):1075-84. PubMed ID: 26214725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Celecoxib versus placebo as an adjunct to treatment-as-usual in children and youth with obsessive-compulsive disorder: protocol for a single-site randomised quadruple-blind phase II study.
    Westwell-Roper C; Best JR; Elbe D; MacFadden M; Baer S; Tucker L; Au A; Naqqash Z; Lin B; Lu C; Stewart SE
    BMJ Open; 2022 Jan; 12(1):e054296. PubMed ID: 35105633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.
    Häge A; Banaschewski T; Buitelaar JK; Dijkhuizen RM; Franke B; Lythgoe DJ; Mechler K; Williams SC; Dittmann RW;
    Trials; 2016 Mar; 17(1):141. PubMed ID: 26983548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
    Riddle MA; Scahill L; King RA; Hardin MT; Anderson GM; Ort SI; Smith JC; Leckman JF; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1062-9. PubMed ID: 1429406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
    Mowla A; Boostani S; Dastgheib SA
    J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial.
    Ghaleiha A; Mohammadi E; Mohammadi MR; Farokhnia M; Modabbernia A; Yekehtaz H; Ashrafi M; Hassanzadeh E; Akhondzadeh S
    Paediatr Drugs; 2013 Dec; 15(6):505-14. PubMed ID: 23821414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
    Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G
    Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The clinical assessment of obsessive-compulsive symptoms in children and adolescents - A study with the Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS-D)].
    Goletz H; Döpfner M
    Z Kinder Jugendpsychiatr Psychother; 2020; 48(3):178-193. PubMed ID: 30556768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder.
    Modarresi A; Chaibakhsh S; Koulaeinejad N; Koupaei SR
    Psychiatry Res; 2019 Dec; 282():112602. PubMed ID: 31630042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, Controlled Trial of Intravenous Immunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections.
    Williams KA; Swedo SE; Farmer CA; Grantz H; Grant PJ; D'Souza P; Hommer R; Katsovich L; King RA; Leckman JF
    J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):860-867.e2. PubMed ID: 27663941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The children's Yale-Brown obsessive-compulsive scale: psychometric properties of child- and parent-report formats.
    Storch EA; Murphy TK; Adkins JW; Lewin AB; Geffken GR; Johns NB; Jann KE; Goodman WK
    J Anxiety Disord; 2006; 20(8):1055-70. PubMed ID: 16503111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.